Markets

Dow Wipes Out 395-Point Gain as Earnings Pop Fades

The Dow surrendered a 395-point opening rally by midday Tuesday, with Goldman Sachs and UnitedHealth giving back early gains while Johnson & Johnson plunged 6.85%.

Daniel Marsh · · · 3 min read · 18 views
Dow Wipes Out 395-Point Gain as Earnings Pop Fades
Mentioned in this article
C $131.92 +1.76% GS $893.95 -0.15% JNJ $250.14 -5.15% JPM $337.43 +0.94% SOXX $589.45 -0.01% UNH $378.52 -0.21% WFC $83.32 -0.28% XLC $111.73 +0.42% XLE $65.08 -0.25% XLV $167.09 -0.17%

The Dow Jones Industrial Average erased a strong opening advance by midday Tuesday, as early enthusiasm over corporate earnings gave way to broad selling pressure. At 12:39 p.m. EDT, the blue-chip index stood at 51,697.65, down 0.29% from Monday's close and 0.76% — or 395 points — below its opening print of 52,092.99. The reversal highlighted a key dynamic: beating analyst estimates is not the same as rewarding shareholders.

Goldman Sachs (NYSE:GS) and UnitedHealth Group (NYSE:UNH) both jumped at the open following better-than-expected results, but each surrendered most of those gains as the session progressed. Johnson & Johnson (NYSE:JNJ) proved a bigger drag, tumbling 6.85% and amplifying the decline in the price-weighted Dow.

Broader benchmarks held up better. The S&P 500 was nearly unchanged at 7,802.76, off just 0.06% from Monday but still 0.10% above its open. The Nasdaq Composite slipped 0.03% to 27,236.60, yet remained 0.36% above its opening level. The Russell 2000 dropped 0.59% and stayed 0.55% below its open, underscoring persistent weakness in small caps.

Market breadth painted a gloomier picture than the headline S&P figure. The Invesco S&P 500 Equal Weight ETF (NYSEARCA:RSP) lost 0.26% and traded 0.46% below its open. Only four of 11 sector funds advanced, while seven declined. "Breadth continues to be weak but has improved slightly," Schwab strategist Liz Ann Sonders noted before the opening bell.

Energy and communication services led the gainers, rising 1.14% and 0.87%, respectively. Health care was the worst performer, falling 1.36%, followed by industrials at 0.87%. The 2.50-percentage-point spread between the best and worst sectors exceeded the move in any major index.

Rates provided little comfort. The 10-year Treasury yield ticked up 3.6 basis points from its cash-session open to 5.223%, though it remained 1.7 basis points below the prior close. The dollar index eased 0.35% to 102.21. WTI crude added 0.18% to $93.91, while gold slipped 0.24% to $4,180.70.

Goldman Sachs embodied the session's round trip. Shares traded at $898.68, up 0.47% from Monday but 2.63% below their $923 open. The bank reported quarterly earnings of $17.01 per share on revenue of $18.68 billion. CEO David Solomon described a "complicated operating environment."

Banking peers diverged. JPMorgan Chase (NYSE:JPM) gained 0.37% but sat 1.30% below its open. Citigroup (NYSE:C) fell 3.42% despite posting $5.2 billion in net income. Wells Fargo (NYSE:WFC) lost 1.67% after revenue missed expectations, according to Associated Press reporting.

Health-care earnings delivered sharper swings. Johnson & Johnson traded 3.38% below its open after reporting 5.9% sales growth, as adjusted earnings fell 7.5% and a talc-related charge cut reported EPS to $0.09. UnitedHealth gained 0.53% but stood 4.30% below its open after lifting full-year adjusted guidance to at least $20.50 per share.

Semiconductors staged a partial recovery. The iShares Semiconductor ETF (NASDAQ:SOXX) was down 0.72% from Monday but traded 1.92% above its $530.71 open, helping the Nasdaq outperform the Dow and small caps.

Looking ahead, the Bureau of Labor Statistics will release September consumer-price data Wednesday at 8:30 a.m. EDT. A cooler inflation print could pull yields lower and revive small caps, while a hot reading could deepen the selloff in equal-weight and rate-sensitive names. Investors must decide whether that evidence validates Tuesday's yield rebound and weak breadth.

This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Market data may be delayed. Always conduct your own research and consult a licensed financial advisor before making investment decisions.

Related Articles

View All →